Qiagen Draws Early Takeover Interest from EQT, Advent, and KKR
No formal bids yet as the ~$9B molecular diagnostics leader faces sector consolidation.
/ 3 items
#QGEN↓
Qiagen Considers Sale as Takeover Interest Returns
Qiagen is reviewing strategic options, including a possible sale, as takeover interest resurfaces in the fast-growing life sciences and diagnostics sector.
QIAGEN Acquires Parse Biosciences to Boost Single-Cell Research Capabilities
QIAGEN announces its $225 million acquisition of Parse Biosciences, expanding into scalable single-cell technologies to power AI-driven biological research and drug discovery.